___

• Donati F. Sugammadeks: a cyclodextrin toreverse neuromuscular blockade in anesthesia. Expert Opin Pharmacother 2008; 9 (8):1375-1386.
• Hunter JM. New neuromuscular blocking drugs. N Engl J Med 1995;332:1691-1699.
• Griffith HR, Johnson GE. The use of curare in general anesthesia. Anesthesiology 1942;3:418-420.
• Bevan DR, Donati F, Kopman AF. Reversal of neuromuscular blockade. Anesthesiology 1992;77:785-805.
• Marryn JA, Richtsfeld M. Succinylcholine-induced hyperkalemia in acquired pathologic states:etiologic factors and molecular mechanisms. Anesthesiology 2006;104:158-169.
• Lindstrom JM. Acetylcholine receptors and myasthenia. Muscle Nerve 2000;23:453-477.
• Naguib M, Flood P, McArdle JJ, Brenner HR. Advances in neurobiology of the neuromuscular junction:implications for the anesthesiologist. Anesthesiology 2002;96:202-231.
• Naguib M, Kopman AF, Ensor JF.Neuromuscular monitoring and postoperative residual curarisation:a meta-analysis. Br J Anaesth 2007;98:302-316.
• Viby-Mogensen J, Jorgensen BC, Ording H. Residual curarization in the recovery room. Anesthesiology 1979;50:539-541.
• Magorian TT, Lynam DP, Caldwell J, et al. Can early administration of neostigmine in single or divided doses, alter the corse of neuromuscular recovery from a vecuronium-induced neuromuscular blockade? Anesthesiology 1990;73:410-414.
• Brand JB, Cullen DJ, Wilson NE et al. Spontaneous recovery from nondepolarising neuromuscular blockade: correlation between clinical and evoked responses. Anesth Analg 1977;56:55-58.
• Eriksson LI. Residual neuromuscular blockade. Incidence and relevalance. Anaesthesist 2000;49 (Suppl 1):18-19.
• Eriksson LI, Sundman E, Olsson R, et al. Functional assessment of the pharynx at rest and during swallowing in partially paralyzed humans:simultaneous videomanometry and mechanomyography of awake human volunteers. Anesthesiology 1997;87:1035-1043.
• Kopman AF, Yee PS, Neuman GG. Relationship of the train-of-four fade ratio to clinical signs and symptoms of residual paralysis in awake volunteers. Anesthesiology 1997;86:765-771.
• Sundman E, Witt H, Olsson R, et al. The incidence and mechanisms of pharyngeal and upper esophageal dysfunction in partially paralyzed humans: pharyngeal videoradiography and simultaneous manometry after atracurium. Anesthesiology 2000;92:977-984. 10
• Abrishami A, Ho J, Wong J, Yin L, Chung F. Sugammadeks, a selective reversal medication for preventing postoperative residual neuromuscular blockade (Review). Cochrane Database Syst Rev 2009; (4): CD007362.
• Groudine SB, Soto R, Lien C, et al. A randomized, dose-finding, phase II study of the selective relaxant binding drug, sugammadeks, capable of safely reversing profound rocuronium-induced neuromuscular block. Anesth Analg 2007;104:555-562.
• Khuenl-Brady KS, Wattwil M, Vanacker BF, Tamayo JL, Rietbergen H, Alvarez-Gomez JA. Sugammadeks provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesth Analg 2010;110:64-73.
• Duvaldestin P, Kuizenga K, Saldien V, Claudius C, Servin F, Klein J, et al. A randomized dose-response study of sugammadeks given for the reversal of deep rocuronium- or vecuronium-induced neuromuscular blockade under sevoflurane anesthesia. Anesth Analg 2010;110:74-82.
• Suzuki T, Kitajima O, Ueda K, Kondo Y, Kato J, Ogawa S. Reversibility of rocuronium-induced profound neuromuscular block with sugammadeks in younger and older patients. British Journal of Anaesthesia 2011;106:823-826.
• Raft J, Belinga JF, Jurkolow G, Desandes E, Longrois D, Meistelman C. Clinical evaluation of post-surgical bleeding after a sugammadeks injection. Ann Fr Anesth Reanim 2011;30:714-717.
• Unterbuchner C, Fink H, Blobner M. The use of sugammadeks in a patient with myasthenia gravis. Anaesthesia 2010; 65(3): 302- 305.
• Petrun AM, Mekis D, Kamenik M. Successful use of rocuronium and sugammadeks in a patient with myasthenia. Eur J Anaesthesiol 2010;27:917-918.
• Matsuki Y, Hirose M, Tabata M, Nobukawa Y, Shigemi K. The use of sugammadeks in a patient with myotonic dystrophy. Eur J Anaesthesiol 2011;28:145-146.
• Weekes G, Hayes N, Bowen M. Reversal of prolonged rocuronium neuromuscularblockade with sugammadeks in an obstetric patient with transverse myelitis. Int J Obstet Anesth 2010;19:333-336.
• Peeters PA, van den HeuvelMW, van Heumen E, et al. Safety, tolerability and pharmacokinetics of sugammadeks using single high doses (up to 96 mg kg-1) in healthy adult subjects: a randomized, double-blind, crossover, placebo-controlled, single-centre study. Clin Drug Investig 2010;30:867-874.
• Menendez-Ozcoidi L, Ortiz-Gomez JR, Olaquibel-Ribero JM, Salvador-Bravo MJ. Allergy to low dose sugammadeks. Anaesthesia 2011;66:217-219.
• Chambers D, Paulden M, Paton F, et al. Sugammadeks for reversal of neuromuscularblock after rapid sequence intubation: a systematic review and economic assessment. Br J Anaesth 2010;105:568-575.
• Paton F, Paulden M, Chambers D, et al. Sugammadeks compared with neostigmine/glycopyrrolate for routine reversal of neuromuscular block: a systematic review and economic evaluation. Br J Anaesth 2010;105:558-567.